Product Information
TELMISARTAN 40 MG TABLET is a generic product labeled by Ascend Laboratories, LLC, priced at $0.1503 per EA under NDC 67877048330. Its NADAC has been published 357 times since Dec 4, 2019.
FDA first approved this application on Oct 30, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877048330
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TELMISARTANApproval Type
Generic (ANDA)
FDA Application
ANDA205150FDA Approved
10/30/2015
TE Code
AB
On Market Since
6/12/2016
Pharmacological Classes
Price Statistics
The NADAC for TELMISARTAN 40 MG TABLET has been published 357 times since Dec 4, 2019, and over the history we have for it it has declined 72.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1503 per EA |
|---|---|
| All-time high | $0.6457 (Jan 15, 2020) |
| All-time low | $0.1274 (Nov 20, 2024) |
| 52-week high | $0.1808 |
| 52-week low | $0.1503 |
| Median price | $0.2623 |
| Average price | $0.2929 |
| Largest weekly change | -33.0% (Nov 20, 2024) |
| Weeks tracked | 357 |
| Tracking since | Dec 4, 2019 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
telmisartan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TELMISARTAN 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TELMISARTAN 40 MG TABLET, manufactured by Ascend Laboratories, LLC, is $0.1503 per EA (NDC 67877048330), effective Sep 30, 2026.
How has the price of TELMISARTAN 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for TELMISARTAN 40 MG TABLET has declined 72.7%. It has been tracked across 357 weekly CMS publications since Dec 4, 2019.
What are the highest and lowest recorded NADAC prices for TELMISARTAN 40 MG TABLET?
Since Dec 4, 2019, the NADAC for TELMISARTAN 40 MG TABLET has ranged from a low of $0.1274 (Nov 20, 2024) to a high of $0.6457 (Jan 15, 2020), with a median of $0.2623 per EA.
Are there cheaper alternatives to TELMISARTAN 40 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TELMISARTAN 40 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures TELMISARTAN 40 MG TABLET?
TELMISARTAN 40 MG TABLET (NDC 67877048330) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.